Matrixx Initiatives Inc. expected to Report Q3 2010 Results on January 25, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).

Matrixx Initiatives Inc. provided earnings guidance for the full year of fiscal 2010. The company expects for the year reflects a revenue level for the current fiscal year in the $65.0 million to $70.0 million range.

Matrixx Initiatives Inc. reported earnings results for the second quarter and six months ended September 30, 2009. For the second quarter, revenue decreased 24% to $25.6 million compared to $33.6 million for the comparable quarter in the prior year. The company reported net income for the quarter of $5.1 million, or $0.55 per diluted share, compared to net income of $8.2 million, or $0.86 per diluted share, for the quarter ended September 30, 2008. The lower sales in the quarter ended September 30, 2009 against the prior year is primarily attributable to the loss of nasal Cold Remedy products, which were withdrawn from the market in June 2009. The company also reported income from operations of $8,228,000 and net income before tax of $8,266,000 against income from operations of $13,273,000 and net income before tax of $13,358,000 for the same period a year ago. For the six months ended September 30, 2009, the company reported net sales of $32.5 million, and a net loss of $17.8 million, or $1.95 per diluted share, which includes a $9.0 million charge for the recall of Cold Remedy Nasal Gel and Cold Remedy Swabs as well as charges of approximately $23.9 million for the impairment of goodwill and certain tangible and intangible assets recorded in the quarter ended June 30, 2009. This compares to net sales of $42.1 million and net income of $6.0 million, or $0.62 per diluted share, for the six months ended September 30, 2008. The company also reported loss from operations of $28,939,000 and net loss before tax of $17,754,000 against income from operations of $9,514,000 and net income before tax of $9,706,000 for the same period a year ago.